Clinical trial · Interventional
Study on Skin Toxicities Induced by Cancer Treatments
DERMACLIC : Study on Skin Toxicities Induced by Cancer Treatments
NCT04402606CI-TRIAL-00076215DERMACLICcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The skin toxicities will be evaluated on patient (male or female) with an indication of cancer treatment in the case of solid tumor of the breast, or lung.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation on skin toxicities | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Evaluation on skin toxicities
- description
- This evaluation consists on a clinical examination of the skin and the realization of the cutaneous measurements of reference on 4 sites frequently exposed to the cutaneous toxicities: face, neckline, palms of the hands and soles of the feet.
- interventionNames
- Other: Evaluation on skin toxicities
Primary outcomes (1)
- measure
- Estimate the rates of severe skin toxicities (grade 2) induced by cancer treatments, at 8 months after the start of treatment.
- timeFrame
- 8 months
- description
- Severity of cutaneous toxicities at 8 months after the start of treatment (grade \> 2 according to the NCI-CTCAE classification version 4.03), induced by the anticancer treatments.
Secondary outcomes (21)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient, male or female, aged 18 years and older, with a solid tumor breast or lung, localized, locally advanced or not, metastatic or not; 2. Patient in medical oncology consultation requiring systemic anti-tumor therapy (chemotherapy, targeted therapy, hormone therapy, immunotherapy) in neo-adjuvant, adjuvant or metastatic; 3. Treatment planned for a minimum period of 3 months (from the date of inclusion); 4. Having a social security protection; 5. Signed informed consent form of the study. Exclusion Criteria: 1. Patient treated for lymphoma, leukemia or inflammatory breast cancer ; 2. Patient with a solid tumour which location is other than breast or lung; 3. Patient with a tumor wound ; 4. Patient with a general condition \> 2 at baseline (ECOG classification) ; 5. Patient receiving anti-tumor treatment with radiotherapy exclusively or associated with concomitant radiotherapy ; 6. Patient unable to receive information about the study and to give consent ; 7. Persons deprived of liberty or guardianship ; 8. Impossible submission to study procedures for geographical or psychological reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.